GGrantIndex
Sort

46,585 grants matching heart failure

An Accurate Non-Contrast-Enhanced Cardiac MRI Method for Imaging Chronic Myocardial Infarctions: Technical Developments to Rapid Clinical Validation

$809,909
Rohan Dharmakumar · Cedars-Sinai Medical Center · R01 · FY2018 · HL

Whole-Heart Myocardial Blood Flow Quantification Using MRI

$809,851
Debiao Li · Cedars-Sinai Medical Center · R01 · FY2016 · HL

Oxidation-mediated structural degeneration of bioprosthetic heart valves

$809,825
Robert J Levy · Children'S Hosp Of Philadelphia · R01 · FY2019 · HL

Engineered Stem Cells for Cardiac Repair

$809,808
Michael Regnier · University Of Washington · R01 · FY2022 · HL

Chronic Kidney Disease in Children Study (C-Kid)

$809,580
Susan L Furth · Johns Hopkins University · U01 · FY2007 · DK

Resuscitating the Brain and Heart Following Cardiac Arrest: Targeting Oxygen Toxicity

$809,442
Willard William Sharp · University Of Chicago · R01 · FY2025 · HL

Hispanic Community Health Study

$809,175
Neil Schneiderman · University Of Miami Coral Gables · N01 · FY2010 · HL

Microstructural Response of the Myocardium to Mechanical Load

$809,143
David E Sosnovik · Massachusetts General Hospital · R01 · FY2023 · HL

Microstructural Response of the Myocardium to Mechanical Load

$809,143
David E Sosnovik · Massachusetts General Hospital · R01 · FY2022 · HL

A Randomized Controlled Trial of Gamification and Social Incentives to Increase Adherence to Physical Activity Among Patients with Heart Failure with Preserved Ejection Fraction

$809,029
Alexander Craig Fanaroff · University Of Pennsylvania · R01 · FY2024 · HL

Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension

$809,000
Joe G. N. Garcia · Aqualung Therapeutics Corp. · R42 · FY2023 · HL

Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension

$808,999
Joe G. N. Garcia · Aqualung Therapeutics Corp. · R42 · FY2024 · HL

Calcium Pump Activators for Heart Failure Therapy

$808,914
David Dale Thomas · University Of Minnesota · R01 · FY2015 · HL

Development of a Novel Immunomodulatory Pyridone for the Treatment of Heart Failure with Preserved Ejection Fraction

$808,812
Jennifer Baltz · I-Cordis, Llc · R44 · FY2022 · HL

Mediators of Systemic Inflammation and Heart Failure Risk in the Community

$808,739
Susan Cheng · Cedars-Sinai Medical Center · R01 · FY2022 · HL

Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life

$808,711
Jordana B. Cohen · University Of Pennsylvania · R01 · FY2022 · AG

Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction

$808,592
Constance M John · Mandalmed, Inc. · R44 · FY2017 · AG

Predictive and systems modeling of exosome cargo

$808,518
Michael E Davis · Emory University · R01 · FY2019 · HL

CORAL: Data Coordinating Center

$808,482
Donald Cutlip · Beth Israel Deaconess Medical Center · U01 · FY2007 · HL

Neuromaturational Delays in Iron Deficient Anemic Infants

$808,336
Betsy Lozoff · University Of Michigan At Ann Arbor · R01 · FY2010 · HD

TASK AREA A - MESA CORE OPERATIONS, FIELD CENTER.

$808,268
Karol Watson · University Of California Los Angeles · N01 · FY2024 · HL

Genetic Contribution to Graft and Patient Outcomes

$808,200
Adriana V Zeevi · University Of Pittsburgh At Pittsburgh · P50 · FY2007 · HL

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

$808,114
Takara Leah Stanley · Massachusetts General Hospital · R01 · FY2019 · DK

Impact of Interventions on Future Trends in Subnational Burden of Cardiovascular Diseases in the US

$808,029
Gregory Andrew Roth · University Of Washington · R01 · FY2024 · HL

Structure and function of voltage-gated calcium channels

$808,022
Daniel L Minor · University Of California, San Francisco · R01 · FY2022 · HL